MindMed KOL Webinar on Substance Use Disorders & Withdrawal Management
About The Event
The webinar will feature presentations from Key Opinion Leaders (KOLs) Kelly E. Dunn, PhD, MBA (Johns Hopkins School of Medicine) and Stuart Gitlow, MD, MPH, MBA (Past President of the American Society of Addiction Medicine) who will discuss substance use disorders, the current treatment landscape for opioid use disorder, and unmet medical need in the management of opioid withdrawal.
Following Drs. Dunn and Gitlow’s presentations, the MindMed leadership team will provide an overview of the MM-110 (zolunicant) clinical development program and discuss its therapeutic potential in substance use disorders. MM-110 is an α3β4 nicotinic cholinergic receptor antagonist that offers a novel mechanism to address a critical gap in current opioid use disorder treatment.
A live question and answer session will follow the presentations.